


Obstetrics & Gynaecology

An Evidence-based
Text for the **MRCOG**

THIRD EDITION

David M. Luesley and Mark D. Kilby



CRC CRC Press
Taylor & Francis Group

Accessing the E-book edition

OBSTETRICS & GYNAECOLOGY: AN EVIDENCE-BASED TEXT FOR MRCOG, THIRD EDITION

Using the VitalSource® ebook

Access to the VitalBook™ ebook accompanying this book is via VitalSource® Bookshelf – an ebook reader which allows you to make and share notes and highlights on your ebooks and search across all of the ebooks that you hold on your VitalSource Bookshelf. You can access the ebook online or offline on your smartphone, tablet or PC/Mac and your notes and highlights will automatically stay in sync no matter where you make them.

1. **Create a VitalSource Bookshelf account at** <https://online.vitalsource.com/user/new> or log into your existing account if you already have one.

2. **Redeem the code provided in the panel below to get online access to the ebook.**

Log in to Bookshelf and select **Redeem** at the top right of the screen. Enter the redemption code shown on the scratch-off panel below in the **Redeem Code** pop-up and press **Redeem**. Once the code has been redeemed your ebook will download and appear in your library.



No returns if this code has been revealed.

DOWNLOAD AND READ OFFLINE

To use your ebook offline, download BookShelf to your PC, Mac, iOS device, Android device or Kindle Fire, and log in to your Bookshelf account to access your ebook:

On your PC/Mac

Go to <https://support.vitalsource.com/hc/en-us> and follow the instructions to download the free **VitalSource Bookshelf** app to your PC or Mac and log into your Bookshelf account.

On your iPhone/iPod Touch/iPad

Download the free **VitalSource Bookshelf** App available via the iTunes App Store and log into your Bookshelf account. You can find more information at <https://support.vitalsource.com/hc/en-us/categories/200134217-Bookshelf-for-iOS>

On your Android™ smartphone or tablet

Download the free **VitalSource Bookshelf** App available via Google Play and log into your Bookshelf account. You can find more information at <https://support.vitalsource.com/hc/en-us/categories/200139976-Bookshelf-for-Android-and-Kindle-Fire>

On your Kindle Fire

Download the free **VitalSource Bookshelf** App available from Amazon and log into your Bookshelf account. You can find more information at <https://support.vitalsource.com/hc/en-us/categories/200139976-Bookshelf-for-Android-and-Kindle-Fire>

N.B. The code in the scratch-off panel can only be used once. When you have created a Bookshelf account and redeemed the code you will be able to access the ebook online or offline on your smartphone, tablet or PC/Mac.

SUPPORT

If you have any questions about downloading Bookshelf, creating your account, or accessing and using your ebook edition, please visit <http://support.vitalsource.com/>

Obstetrics & Gynaecology

CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2016 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works
Version Date: 20160308

International Standard Book Number-13: 978-1-4822-3383-4 (eBook - PDF)

This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal responsibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do not necessarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other professional's own judgement, their knowledge of the patient's medical history, relevant manufacturer's instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the relevant national drug formulary and the drug companies' and device or material manufacturers' printed instructions, and their websites, before administering or utilizing any of the drugs, devices or materials mentioned in this book. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as to advise and treat patients appropriately. The authors and publishers have also attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Visit the Taylor & Francis Web site at
<http://www.taylorandfrancis.com>

and the CRC Press Web site at
<http://www.crcpress.com>

Obstetrics & Gynaecology

An Evidence-based
Text for the **MRCOG**
THIRD EDITION

David M. Luesley

University of Birmingham, UK

Mark D. Kilby

University of Birmingham, UK



CRC Press

Taylor & Francis Group

Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

This page intentionally left blank

Contents

| | |
|-----------------------------------|-------------|
| CONTRIBUTORS | ix |
| PREFACE | xiii |
| ACKNOWLEDGEMENTS | xv |
| LIST OF ABBREVIATIONS USED | xvii |
| HOW TO USE THIS BOOK | xxv |

SECTION ONE INTRODUCTORY/GENERAL

Section Editor: James Drife

| | | |
|---|--|----|
| 1 Evidence-based medicine and medical informatics | <i>Jane Thomas</i> | 3 |
| 2 The general principles of surgery | <i>Fiona M Reid</i> | 14 |
| 3 Communication and counselling | <i>Richard Porter</i> | 23 |
| 4 The law, medicine and women's rights | <i>Sheila McLean</i> | 27 |
| 5 Clinical risk | <i>Sam Pretlove</i> | 33 |
| 6 Rationale for advanced skills training | <i>Timothy Draycott and Islam Gamaleldin</i> | 39 |

SECTION TWO ANTENATAL OBSTETRICS

Section Editor: Mark Kilby

| | | |
|---|--|-----|
| 7 Routine antenatal care: an overview | <i>Nina Johns</i> | 51 |
| 8 Chronic hypertension | <i>Kate Bramham and Andrew Shennan</i> | 60 |
| 9 Diabetes mellitus | <i>Clare L Tower</i> | 68 |
| 10 Cardiac disease | <i>Catherine Nelson-Piercy</i> | 78 |
| 11 Thyroid disease | <i>Andrew Shennan and Joanna Girling</i> | 83 |
| 12 Haematological conditions | <i>Sarah Wharin and Sue Pavord</i> | 88 |
| 13 Renal disease | <i>Catherine Nelson-Piercy</i> | 111 |
| 14 Autoimmune conditions | <i>Catherine Nelson-Piercy</i> | 116 |
| 15 Liver and gastrointestinal disease | <i>Catherine Nelson-Piercy</i> | 122 |
| 16 Respiratory conditions | <i>Louise Kenny</i> | 128 |
| 17 Neurological conditions | <i>Louise Kenny</i> | 137 |
| 18 Dermatological conditions | <i>Louise Kenny</i> | 148 |
| 19 Drug and alcohol misuse | <i>Louise Kenny</i> | 152 |
| 20 Smoking | <i>Andrew Shennan</i> | 160 |
| 21 Anaemia | <i>Will Lester</i> | 163 |
| 22 Abdominal pain | <i>Clare L Tower</i> | 168 |
| 23 Malignancy | <i>Louise Kenny</i> | 175 |
| 24 Maternal infections in pregnancy | <i>Tara Jayne Selman</i> | 184 |
| 25 Gestational diabetes | <i>Clare L Tower</i> | 191 |
| 26 Pre-eclampsia and non-proteinuric pregnancy-induced hypertension | <i>Andrew Shennan</i> | 198 |
| 27 Medication in pregnancy | <i>Clare L Tower</i> | 206 |
| 28 Maternal mortality | <i>James Drife</i> | 213 |

SECTION THREE FETAL CONDITIONS

Section Editor: Mark Kilby

| | | |
|---|---|-----|
| 29 Biochemical screening | <i>Michele P Mohajer</i> | 227 |
| 30 Ultrasound screening | <i>Michele P Mohajer</i> | 231 |
| 31 Invasive and non-invasive prenatal diagnosis | <i>Michele P Mohajer</i> | 237 |
| 32 Understanding genetics and genetic tests | <i>Fiona Mackie and Denise Williams</i> | 241 |
| 33 Management of fetal anomalies | <i>Michele P Mohajer</i> | 253 |
| 34 Previous history of fetal loss | <i>Abi Merriel and Arri Coomarasamy</i> | 257 |
| 35 Multiple pregnancy | <i>Bill Martin</i> | 262 |
| 36 Fetal infections | <i>Tara Jayne Selman</i> | 267 |

| | | |
|--|--|-----|
| 37 Tests of fetal wellbeing | <i>Alexander Heazell</i> | 274 |
| 38 Small for gestational age and intrauterine growth restriction | <i>Jennifer A Tamblyn and R Katie Morris</i> | 281 |
| 39 Aberrant liquor volume | <i>Jennifer A Tamblyn and R Katie Morris</i> | 292 |
| 40 Fetal hydrops | <i>Caroline Fox and Sailesh Kumar</i> | 300 |
| 41 Malpresentation | <i>Alexander M Pirie</i> | 306 |
| 42 Prolonged pregnancy | <i>Devender Roberts and Rajeshwari Myagerimath</i> | 310 |
| 43 Routine intrapartum care: an overview | <i>Mary Higgins</i> | 316 |

SECTION FOUR LATE PREGNANCY AND INTRAPARTUM EVENTS

Section Editor: Mark Kilby

| | | |
|--|---------------------------------------|-----|
| 44 Preterm labour | <i>Myles Taylor and Stuart Rundle</i> | 327 |
| 45 Pre-labour rupture of the membranes | <i>Myles Taylor and Stuart Rundle</i> | 338 |
| 46 Antepartum haemorrhage | <i>Lucy Kean</i> | 345 |
| 47 Intrauterine fetal death | <i>Lucy Kean</i> | 360 |

SECTION FIVE FIRST STAGE OF LABOUR

Section Editor: Mark Kilby

| | | |
|--|--|-----|
| 48 Induction of labour | <i>Nina Johns</i> | 373 |
| 49 Management after previous caesarean section | <i>Lucy Kean</i> | 381 |
| 50 Poor progress in labour | <i>Graham Tydeman and Alexandra Rice</i> | 389 |
| 51 Fetal compromise in the first stage of labour | <i>Jenny Blackman and Myles Taylor</i> | 395 |
| 52 Obstetric anaesthesia and analgesia | <i>David M Levy and Duncan S Cochran</i> | 404 |
| 53 Caesarean section | <i>Tracey A Johnston</i> | 416 |

SECTION SIX SECOND STAGE OF LABOUR

Section Editor: Mark Kilby

| | | |
|---|--|-----|
| 54 Fetal compromise in the second stage of labour | <i>Myles Taylor</i> | 427 |
| 55 Shoulder dystocia | <i>Jenny Blackman and Myles Taylor</i> | 431 |
| 56 Instrumental vaginal delivery | <i>Tracey A Johnston</i> | 437 |
| 57 Breech presentation | <i>Alexander M Pirie</i> | 443 |
| 58 Perineal trauma | <i>Lucy Kean</i> | 457 |

SECTION SEVEN POSTPARTUM COMPLICATIONS

Section Editor: Mark Kilby

| | | |
|--------------------------------|-------------------------|-----|
| 59 Perinatal asphyxia | <i>Andrew Currie</i> | 471 |
| 60 Neonatal resuscitation | <i>Andrew Currie</i> | 476 |
| 61 Common neonatal problems | <i>Andrew Currie</i> | 485 |
| 62 Perinatal mortality | <i>James Drife</i> | 493 |
| 63 Postpartum collapse | <i>Peter J Thompson</i> | 502 |
| 64 Postpartum haemorrhage | <i>Peter J Thompson</i> | 507 |
| 65 Postpartum pyrexia | <i>Peter J Thompson</i> | 512 |
| 66 Disturbed mood | <i>Peter J Thompson</i> | 516 |
| 67 Problems with breastfeeding | <i>Peter J Thompson</i> | 520 |

SECTION EIGHT REPRODUCTIVE GYNAECOLOGY

Section Editor: Arri Coomarasamy

| | | |
|---|--|-----|
| 68 Normal and abnormal development of the genitalia | <i>Rebecca Deans and Sarah M Creighton</i> | 525 |
| 69 Karyotypic abnormalities | <i>Diana Fothergill</i> | 536 |
| 70 Menarche and adolescent gynaecology | <i>Diana Fothergill</i> | 539 |

| | | |
|---|--|-----|
| 71 Ovarian and menstrual cycles | <i>Mohammed Khairy and Rima Dhillon</i> | 543 |
| 72 Contraception and termination of pregnancy | <i>Kulsum Jaffer</i> | 551 |
| 73 Endometrial function | <i>Hilary OD Critchley and Christine P West</i> | 570 |
| 74 Uterine fibroids | <i>Christine P West</i> | 574 |
| 75 Abnormal uterine bleeding | <i>Christine P West</i> | 583 |
| 76 Dysmenorrhoea and pelvic pain | <i>Christine P West</i> | 592 |
| 77 Endometriosis | <i>Christine P West</i> | 602 |
| 78 Adenomyosis | <i>Christine P West</i> | 613 |
| 79 Premenstrual syndrome | <i>Christine P West</i> | 617 |
| 80 Normal conception | <i>Yakoub Khalaf</i> | 625 |
| 81 Female infertility | <i>Yakoub Khalaf</i> | 629 |
| 82 Male infertility | <i>Yakoub Khalaf</i> | 638 |
| 83 Unexplained infertility | <i>Smriti Bhatta and Siladitya Bhattacharya</i> | 643 |
| 84 Assisted reproduction | <i>Abey Eapen and Arri Coomarasamy</i> | 648 |
| 85 Polycystic ovary syndrome | <i>Adam H Balen</i> | 654 |
| 86 Hirsutism and virilism | <i>Mostafa Metwally and William Ledger</i> | 663 |
| 87 Amenorrhoea and oligomenorrhoea | <i>Mostafa Metwally and William Ledger</i> | 668 |
| 88 Menopause | <i>Tina Sara Verghese, Jenny Williamson and Lynne Robinson</i> | 672 |
| 89 Miscarriage | <i>James Hounslow and Ying Cheong</i> | 678 |
| 90 Ectopic pregnancy | <i>Ghada Salman, Davor Jurkovic</i> | 685 |
| 91 Premature ovarian insufficiency | <i>Nowmi Zaman, Jenny Williamson and Lynne Robinson</i> | 698 |
| 92 Fertility preservation | <i>Hoda Harb and Arri Coomarasamy</i> | 707 |
| 93 Psychosexual medicine | <i>Susan V Carr</i> | 712 |

SECTION NINE UROGYNAECOLOGY AND SEXUAL HEALTH AND WELLBEING

Section Editors: Linda Cardozo and Dudley Robinson

| | | |
|---|---|-----|
| 94 Assessment of lower urinary tract function | <i>Angie Rantell</i> | 719 |
| 95 Urinary incontinence | <i>Dudley Robinson and Linda Cardozo</i> | 736 |
| 96 Other lower urinary tract disorders | <i>Ganesh Thiagamoorthy and Sushma Srikrishna</i> | 765 |
| 97 Lower urinary tract infections | <i>Ilias Giarenis and Dudley Robinson</i> | 773 |
| 98 Urogenital prolapse | <i>Sushma Srikrishna and Dudley Robinson</i> | 780 |
| 99 Infection and sexual health | <i>Melanie Mann</i> | 791 |
| 100 Dyspareunia and other psychosexual problems | <i>Melanie Mann</i> | 810 |
| 101 Child sexual abuse | <i>Catherine White</i> | 817 |
| 102 Rape and sexual assault | <i>Catherine White</i> | 822 |
| 103 Female genital mutilation | <i>Ben Chisnall and Janice Rymer</i> | 830 |

SECTION TEN LOWER GENITAL TRACT

Section Editor: Simon Leeson

| | | |
|----------------------------|---|-----|
| 104 Benign vulval problems | <i>Lubna Haque and Margaret Cruickshank</i> | 839 |
| 105 Vulvodynia | <i>Shuchi Dixit and David Nunns</i> | 848 |
| 106 Pre-invasive disease | <i>Nirmala Rai and Gabrielle Downey</i> | 854 |

SECTION ELEVEN GYNAECOLOGICAL ONCOLOGY

Section Editors: David Luesley and Simon Leeson

| | | |
|---|--|-----|
| 107 Endometrial cancer | <i>Mahalakshmi Gurumurthy and Margaret Cruickshank</i> | 873 |
| 108 Cervical cancer | <i>Pierre L Martin-Hirsch</i> | 883 |
| 109 Benign and malignant ovarian masses | <i>Sudha Sundar</i> | 889 |
| 110 Vulval and vaginal cancer | <i>John Tidy</i> | 906 |
| 111 Gestational trophoblastic disease | <i>Fieke E M Froeling and Michael J Seckl</i> | 913 |
| 112 Rare tumours | <i>Nicholas Reed</i> | 922 |

INDEX

This page intentionally left blank

Contributors

Adam H Balen DSc FRCOG

Professor of Reproductive Medicine and Surgery, Chair of The British Fertility Society, The Leeds Centre for Reproductive Medicine, Seacroft Hospital, Leeds

Smriti Bhatta MBBS MD MRCOG

Senior Clinical Fellow, Aberdeen Fertility Centre, University of Aberdeen, Aberdeen, Scotland

Siladitya Bhattacharya MBBS MRCOG MD

Professor of Reproductive Medicine & Head, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland

Jenny Blackman

Post CCT Fellow, Royal Devon and Exeter Hospital, Exeter

Kate Bramham

Women's Health Academic Centre, St Thomas' Hospital, King's College London, London

Linda Cardozo OBE MD FRCOG

Professor of Urogynaecology, King's College Hospital, London

Susan V Carr FFSRH DRCOG MPhil

Associate Professor, Department of Obstetrics and Gynaecology, University of Melbourne, and Head of Psychosexual Service, Royal Womens Hospital, Melbourne and Chair Australian Society of Psychosocial Obstetrics and Gynaecology, Melbourne, Australia

Ying Cheong MD FRCOG

Associate Professor & Honorary Consultant in Obstetrics and Gynaecology, Subspecialist in Reproductive Medicine and Surgery, Faculty of Medicine University of Southampton, Southampton

Ben Chisnall

Foundation Year 1 Doctor at Oxford University Hospitals NHS Trust, Oxford

Duncan S Cochran MBBS(Lond) FCARCSI

Consultant Anaesthetist, Sandwell and West Birmingham NHS Trust, Birmingham

Arri Coomarasamy MBChB MD FRCOG

Professor of Gynaecology and Reproductive Medicine, College of Medical and Dental Sciences, University of Birmingham and Consultant in Gynaecology, Reproductive Medicine and Surgery, Birmingham Women's NHS Foundation Trust, Birmingham

Sarah M Creighton MD FRCOG

Consultant Gynaecologist, University College London Hospital, UCL Institute of Women's Health, London

Hilary OD Critchley BSc MBChB MD FRCOG FRANZCOG FFRSH FMedSci

Professor of Reproductive Medicine, Honorary Consultant Obstetrician and Gynaecologist, University of Edinburgh, Centre for Reproductive Biology, Edinburgh, Scotland

Margaret Cruickshank MB ChB MD FRCOG

Professor of Gynaecology, Department of Obstetrics and Gynaecology, Aberdeen Maternity Hospital, Aberdeen, Scotland

Andrew Currie BM DCH FRCPCH FRCP Ed

Consultant Neonatologist, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester

Rebecca Deans MBBS MMED RANZCOG CREI

Lecturer and Gynaecologist, University of New South Wales, Royal Hospital for Women, and Sydney Children's Hospital, Sydney, Australia

Rima Dhillon

Specialist Trainee in Obstetrics and Gynaecology, University Hospital Coventry and Warwickshire, Coventry

Shuchi Dixit

Consultant Obstetrician and Gynaecologist, Derby Teaching Hospitals NHS Foundation Trust, Derby

Gabrielle Downey MD FRCOG

Consultant Obstetrician and Lead Colposcopist at City Hospital, Dudley Road, Birmingham

Timothy Draycott

Consultant Obstetrician, University of Bristol, Bristol

James Drife MD FRCOG FRCPed FRCSEd FCOGSA FFSRH

Emeritus professor of Obstetrics and Gynaecology, University of Leeds, Leeds

Abey Eapen

Clinical Research Fellow, University of Birmingham/Birmingham Women's Hospital, Birmingham

Diana Fothergill BSc Med Sci Hons MB ChB FRCOG

Emeritus Consultant Obstetrician and Gynaecologist, The Jessop Wing, Sheffield Teaching Hospitals NHS Trust, Sheffield

Caroline Fox MBChB MD MRCOG

Subspecialty Trainee in Maternal and Fetal Medicine, Birmingham Women's Foundation NHS Trust, Birmingham

Fieke E M Froeling MD PhD MRCP

NIHR Academic Clinical Lecturer, Specialist Registrar in Medical Oncology, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London

Islam Gamaleldin

Speciality Registrar Obstetrics and Gynaecology, Southmead Hospital, Bristol

Ilias Giarenis MRCOG

Subspecialty Trainee in Urogynaecology, King's College Hospital, London

Joanna Girling

Consultant Obstetrician and Gynaecologist, Lead Division 3 and Speciality Lead Reproductive Health & Childbirth NW London CRN, West Middlesex University Hospital, Isleworth

Mahalakshmi Gurumurthy MRCOG

Consultant Gynaecological Oncologist, Aberdeen Royal Infirmary, Aberdeen, Scotland

Lubna Haque MBBS MRCOG

Consultant Gynaecologist & Colposcopist, Luton & Dunstable University Hospital NHS Foundation Trust, Luton

Hoda Maaly Harb

Specialist Registrar in Obstetrics and Gynaecology, University of Birmingham, Birmingham

Alexander Heazell MBChB (Hons) PhD MRCOG

Senior Clinical Lecturer in Obstetrics, Maternal and Fetal Health Research Centre, University of Manchester and St Mary's Hospital, Manchester

Mary Higgins

Consultant in Obstetrics, Gynaecology, Sub-specialist in Maternal Fetal Medicine, National Maternity Hospital / University College Dublin, Dublin

James Hounslow

Senior Registrar in Obstetrics and Gynaecology, Princess Anne Hospital, Southampton

Kulsum Jaffer BSc MBBS FRCOG FFSRH

Consultant in Sexual and Reproductive Health, Heart of Birmingham Teaching Primary Care Trust, St Patrick's Centre, Birmingham

Nina Johns BSc MBChB MRCOG

Consultant Obstetrician, Birmingham Women's Hospital, Birmingham

Tracey A Johnston MD FRCOG

Consultant in Maternal Fetal Medicine, Birmingham Women's NHS Foundation Trust, Birmingham

Davor Jurkovic

Department of Obstetrics and Gynaecology, University College Hospital, London

Lucy Kean DM FRCOG

Consultant Obstetrician Subspecialist in Maternal and Fetal Medicine, Nottingham University Hospitals, Nottingham

Louise Kenny MB ChB honours PhD MRCOG

Professor of Obstetrics and Gynaecology, University College Cork, Consultant Obstetrician and Gynaecologist, Cork University Maternity Hospital, Director, The Irish Centre for Fetal and Neonatal Translational Research (INFANT), Cork, Ireland

Mohammed Khairy MD MRCOG

Subspecialty Trainee in Reproductive Medicine and Surgery, Birmingham Women's Fertility Centre, Birmingham Women's Hospital, Birmingham

Yakoub Khalaf MB BCh MSc MD FRCOG

Consultant Gynaecologist & Sub-Specialist in Reproductive Medicine and Surgery, Director of the Assisted Conception Unit & HFEA Person Responsible, Guy's and St Thomas' Hospital Foundation Trust, Guy's Hospital, London

Mark D Kilby DSc MB BS MD FRCOG FRCPI

Professor in Fetal Medicine, Centre for Women's and Children's Health, University of Birmingham, and Fetal Medicine Centre, Birmingham Women's Foundation Trust, Birmingham

Sailesh Kumar MB BS MMed O&G FRCS MRCOG FRANZCOG DPhil Oxon

Honorary Senior Lecturer and Consultant in Maternal and Fetal Medicine, Centre for Fetal Care, Imperial College London, Queen Charlotte's and Chelsea Hospital, London

William L Ledger MA DPhil Oxon MB ChB FRCOG

Head of School, Women's & Children's Health, UNSW Australia and Head of Reproductive Medicine Department, Royal Hospital for Women, Randwick, Australia

Simon Leeson FRCOG

Consultant Gynaecologist and Oncologist, Betsi Cadwaladr University Health Board, Wales

Will Lester

Consultant Haematologist, University Hospital Birmingham and Birmingham Women's Hospital, Birmingham

David M Levy FRCA

Consultant Obstetric Anaesthetist, Anaesthetics Directorate, Nottingham University Hospitals, Queens Medical Centre Campus, Nottingham

David M Luesley MA MD FRCOG

Emeritus Professor of Gynaecological Oncology, University of Birmingham, Birmingham

Sheila McLean LLB MLitt PhD LLD FRSE FRCGP FRCP (Edin) FRSA

Emeritus Professor of Law and Ethics in Medicine, University of Glasgow, Glasgow, Scotland

Fiona L Mackie MRes, MBChB

Clinical Research Fellow, University of Birmingham, and Birmingham Women's NHS Foundation Trust, Birmingham

Melanie C Mann FRCOG FFFP Dip GUM

Consultant in Sexual and Reproductive Health, Worcestershire Health and Care Trust, Alexandra Hospital, Redditch

Bill Martin

Consultant in Maternal and Fetal Medicine, Birmingham Women's Hospital, Birmingham

Pierre L Martin-Hirsch MRCOG

Consultant Gynaecological Oncologist, Central Lancashire Teaching Hospitals, Preston

Abi Merriel MRCOG

Clinical Research Fellow, University of Birmingham, Birmingham

Mostafa Metwally MD FRCOG

Consultant Gynaecologist and Subspecialist in Reproductive Medicine, The Jessop Wing and Royal Hallamshire Hospital, Sheffield

Michele P Mohajer BM BS FRCOG MD

Consultant in Maternal and Fetal Medicine, Royal Shrewsbury Hospital, Shrewsbury

R Katie Morris PhD MRCOG

Senior Clinical Lecturer in Fetal Medicine, Centre for Women's and Children's Health, University of Birmingham, and Fetal Medicine Centre, Birmingham Women's Foundation Trust, Birmingham

Rajeshwari Myagerimath

Consultant Obstetrician and Gynaecologist, Arrowe Park Hospital, Wirral University Teaching Hospital NHS Foundation Trust, Wirral

Catherine Nelson-Piercy MA FRCP

Consultant Obstetric Physician, Guy's and St Thomas' Foundation Trust and Imperial College Healthcare Trust, and Professor of Obstetric Medicine, King's College London, London

David Nunns MD MRCOG

Consultant Gynaecological Oncologist, Nottingham City Hospital, Nottingham

Sue Pavord MBChB FRCP FRCPath

Consultant Haematologist, Oxford University Hospitals NHS Foundation Trust, Oxford

Alexander M Pirie MB ChB(Edin) BSc(Hons) FRCP(Edin) FRCOG

Consultant in Obstetrics & Maternal Medicine, Honorary Senior Clinical Lecturer, Birmingham Women's Hospital, Birmingham

Richard Porter MA MSc FRCOG

Consultant Obstetrician and Gynaecologist, Royal United Hospital, Bath

Sam Pretlove MBChB PhD MRCOG

Consultant in Maternal & Fetal Medicine, Birmingham Women's Foundation Trust, Birmingham

Nirmala Rai

Cancer Sciences, University of Birmingham, Birmingham

Angie Rantell BSc HONS RN

Lead Nurse Urogynaecology / Nurse Cystoscopist, King's College Hospital, London

Nicholas Reed MRCP(UK), FRCP, FRCP&S (Glas)

Consultant Clinical Oncologist, Beatson Oncology Centre Gartnavel General Hospital, Glasgow, Scotland

Fiona M Reid MD MRCOG

Consultant Urogynaecologist, The Warrell Unit, St Mary's Hospital, Manchester

Alexandra Rice

Registrar in Obstetrics and Gynaecology, South East Scotland Deanery, Edinburgh, Scotland

Devender Roberts

Consultant in Maternal and Fetal Medicine, Liverpool Women's Hospital, Crown Street, Liverpool

Dudley Robinson MBBS MD MRCOG

Consultant Urogynaecologist and Honorary Senior Lecturer, Department of Obstetrics and Gynaecology, King's College Hospital, London

Lynne Robinson

Consultant Obstetrician and Gynaecologist, Birmingham Women's Foundation Trust, Birmingham

Stuart Rundle MRCOG

Speciality Trainee in Obstetrics and Gynaecology, Royal Devon and Exeter NHS Foundation Trust, Child and Women's Health, Exeter

Janice Rymer MD FRCOG FRANZCOG FHEA

Professor of Gynaecology, School of Medical Education, King's College London, London

Ghada Salman

Department of Obstetrics and Gynaecology, University College Hospital, London

Michael J Seckl BSc MBBS PhD FRCP

Professor of Molecular Oncology, Charing Cross Hospital Campus of Imperial College London, London

Tara Jayne Selman MRCOG PhD

Consultant in Fetal Medicine, Birmingham Women's NHS Foundation Trust, Birmingham

Andrew Shennan MB BS MD FRCOG

Professor of Obstetrics, Women's Health Academic Centre, St Thomas Hospital, Kings College London, London

Sushma Srikrishna FRCOG

Consultant Urogynaecologist, Department of Urogynaecology, King's College Hospital, London

Sudha Sundar

Senior Clinical Lecturer/Consultant in Gynaecological Oncology, Pan Birmingham Gynaecological Cancer Centre, City Hospital and School of Cancer Sciences, University of Birmingham, Birmingham

Jennifer A Tamblin

Clinical Research Fellow Obstetrics & Gynaecology, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham

Myles Taylor BA MRCOG PhD

Consultant Obstetrician & Gynaecologist, Subspecialist in Fetal & Maternal Medicine, Royal Devon and Exeter NHS Foundation Trust, Child and Women's Health, Exeter

Ganesh Thiagamorthy MBBS MRCOG

Subspeciality Trainee in Urogynaecology, Department of Urogynaecology, King's College Hospital, London

Jane Thomas MBChB MSC MRCOG MFSRH

Editor Cochrane Gynaecology and Fertility Group, Gynaecologist, University College London Hospital, London

Peter J Thompson MB BS FRCOG

Consultant Obstetrician, Birmingham Women's Hospital, Birmingham

John Tidy BSc MD FRCOG

Professor of Gynaecological Oncology, Royal Hallamshire Hospital, Sheffield

Clare Tower MBChB PHD MRCOG

Consultant in Obstetrics and Fetal Maternal Medicine, St Mary's Hospital, Manchester

Graham Tydeman BSc FRCOG

Consultant Obstetrician and Gynaecologist, NHS Fife, Scotland

Tina Sara Verghese

Clinical Research Fellow, University of Birmingham and Birmingham Women's NHS Foundation Trust, Birmingham

Christine P West MD FRCOG

Consultant Gynaecologist, Royal Infirmary of Edinburgh, Edinburgh, Scotland

Sarah Wharin

Leicester Royal Infirmary, University Hospitals Leicester NHS Trust, Leicester

Catherine White

Clinical Director, St Mary's Sexual Assault Referral Centre, St Mary's Hospital, Manchester

Denise Williams MSc FRCP

Consultant Clinical Geneticist, Birmingham Women's NHS Foundation Trust, Birmingham

Jenny Williamson FFSRH

Menopause Trainer and Chair of the West Midlands Menopause Society, University of Birmingham and Birmingham Women's NHS Foundation Trust, Birmingham

Nowmi Zaman

Specialty Trainee Year 3 in Obstetrics and Gynaecology, Birmingham Women's NHS Foundation Trust, Birmingham

Preface

It is often difficult to know when a new edition of an established textbook is required. It certainly feels as if the intervals get shorter and the demands of updating are greater with each new edition. However, there are constant revisions of our professional guidelines and new developments in the specialities of obstetrics and gynaecology are emerging.

Comparing the content of this, the third edition, with the first edition published in 2004 is both rewarding and somewhat frightening. The rapid pace at which new knowledge and new evidence becomes available seems likely to overwhelm our ability to organise and present it in a format that will fulfil the requirements of aspiring obstetricians and gynaecologists and continue to provide an easily accessible source of information for those practising as specialists.

The popularity of the previous two editions signifies that we are achieving these objectives and the tested template of aligning the text to the RCOG curriculum appears to meet the needs of most readers. The basic core knowledge upon which our discipline is built does not evolve as rapidly as other aspects of our specialism and an in-depth understanding of this core knowledge is an essential prerequisite to success in the MRCOG examination and a solid basis on which to build a career as a practising specialist. It is natural with the passage of time that contributors to our previous editions will have retired or moved on elsewhere and it is right to bring in new contributors who have enthusiasm and often bring a fresh perspective to their subject matter.

We remain of course immensely grateful for the grounding provided by our previous contributors. It is their previous efforts, and the skilful updating and rewriting of our new contributors, that have maintained the high quality of the presented material. Updating, adding and omitting provides a massive editorial challenge if the 'feel' of the text is to be preserved. We believe that we have done the best that we can and that this textbook will continue to be an invaluable companion to the higher training of obstetricians and gynaecologists and a useful repository of knowledge and evidence for those in established practice.

To reiterate the final paragraph of our last preface: *Textbooks do not make good doctors but good doctors must practise from a sound basis of knowledge.* We believe that this, the third edition, continues to satisfy the goals that were laid out in the first edition.

This page intentionally left blank

Acknowledgements

The editors are very grateful to the following, who kindly contributed to the previous edition: Harold Gee, Joanna C Gillham, Barry W Hancock, Richard Hayman, Susan J Houghton, Griff Jones, Henry C Kitchener, Ellen Knox, Murray Luckas, Ismaiel Mahfouz, Dimitrios Nikolaou, Michael Paterson, Charles Redman, Arasee Renganathan, Karina Reynolds, Jane Rufford, Anthony RB Smith, John AD Spencer, Elias Tzakas, Aarti Umranikar, and Linda Watkins.

This page intentionally left blank

List of abbreviations used

| | | | |
|----------|--|--------------|--|
| 5-FU | 5-fluorouracil | ASA | American Society of Anesthesiologists |
| 7-DHCO | 7-dehydrocholesterol | ASCUS | atypical squamous cells of undetermined significance |
| AAA | arterio-arterial anastomatosis | ASD | atrial septal defect |
| ABC | airway, breathing, circulation | ASRM | American Society of Reproductive Medicine |
| AC | abdominal circumference | AST | aspartate aminotransferase (aspartate transaminase) |
| ACE | angiotensin-converting enzyme | ATP | adenosine triphosphate |
| ACEI | angiotensin-converting enzyme inhibitor | AUB | abnormal uterine bleeding |
| AChE | acetylcholinesterase | AUM | ambulatory urodynamic monitoring |
| ACHOIS | Australian Carbohydrate Intolerance Study in Pregnant Women | AVA | arteriovenous vessel |
| aCL | anticardiolipin | AVM | arteriovenous malformation |
| ACOG | American Congress of Obstetricians and Gynecologists | AZT | zidovudine |
| ACTH | adrenocorticotrophic hormone | β -hCG | beta-human chorionic gonadotrophin |
| ADPKD | autosomal dominant polycystic kidney disease | β -IFN | beta-interferon |
| AEDF | absent end-diastolic flow | BASHH | British Association for Sexual Health and HIV |
| AED | anti-epileptic drug | BCG | bacille Calmette Guérin |
| AF | amniotic fluid | BCPT | Breast Cancer Prevention Trial |
| AFC | antral follicular count | BCSH | British Committee for Standards in Haematology |
| AFE | amniotic fluid embolism | BEP | bleomycin, etoposide, cisplatin |
| AFI | amniotic fluid index | BFLUTS | Bristol Female Lower Urinary Tract Symptoms |
| AFLP | acute fatty liver of pregnancy | BG | blood glucose |
| AFP | alpha-fetoprotein | BHIVA | British HIV Association |
| AFS | American Fertility Society | BMD | bone mineral density |
| AFV | amniotic fluid volume | BMI | body mass index |
| AGA | appropriate for gestational age | BMJ | British Medical Journal |
| AHA | American Heart Association | BNF | British National Formulary |
| AIDS | acquired immunodeficiency syndrome | BP | blood pressure |
| AIS | adenocarcinoma <i>in situ</i> | BPD | biparietal diameter |
| ALF | acute liver failure | bpm | beats per minute |
| ALO | <i>Actinomyces</i> -like organism | BPP | biophysical profile |
| ALSO | advanced life support in obstetrics | BPS | bladder pain syndrome |
| ALT | alanine transaminase | BSAC | British Society for Antimicrobial Chemotherapy |
| AMH | anti-Müllerian hormone | BSCC | British Society for Cervical Cytology |
| ANA | antinuclear antibody | BSO | bilateral salpingo-oophorectomy |
| AP | antecedent pregnancy; anterior to posterior | BV | bacterial vaginosis |
| APACHE | Acute Physiology and Chronic Health Evaluation | bvm | bag-valve-mask |
| APH | antepartum haemorrhage | BW | birthweight |
| APL | antiphospholipid | CAH | chronic active hepatitis; congenital adrenal hyperplasia |
| APLS/APS | antiphospholipid syndrome | CAIS | complete androgen insensitivity syndrome |
| APSN | atypical placental site nodule | cAMP | cyclic adenylyl monophosphate |
| APTT | activated partial thromboplastin time | CASA | computer-assisted sperm analysis |
| AR | androgen receptor | CBT | cognitive behavioural therapy |
| ARB | angiotensin II type 1 receptor blocker (angiotensin receptor antagonist) | CC | clomifene citrate |
| ARC | antenatal result and choice | CCC | clear-cell carcinoma |
| AREDV | absent or reversed end-diastolic flow | | |
| ARM | artificial rupture of membranes | | |
| ART | antiretroviral therapy; assisted reproduction technique | | |

| | | | |
|--------|---|-------|---|
| CCAML | congenital cystic adenomatous malformation of the lung | CSE | child sexual exploitation; combined spinal–epidural |
| CCG | Clinical Commissioning Group | CSF | cerebrospinal fluid |
| CCP | cyclic citrullinated peptide | CSII | continuous subcutaneous insulin infusion |
| CCSS | Childhood Cancer Survivor Study | CSM | Committee on Safety of Medicines |
| CDSR | Cochrane Database of Systematic Reviews | CT | computed tomography |
| CEA | carcinoembryonic antigen | CTG | cardiotocography |
| CEE | conjugated equine oestrogen | CTOCS | collaborative trial of ovarian cancer screening |
| CEFM | continuous electronic fetal monitoring | CTPA | computed tomography pulmonary angiogram |
| CEMACH | Confidential Enquiry into Maternal and Child Health | CVA | cerebrovascular accident |
| CEMD | Confidential Enquiry into Maternal Death | CVP | central venous pressure |
| CEPOD | Confidential Enquiry into Perioperative Death | CVS | chorionic villus sampling |
| CESDI | Confidential Enquiry into Stillbirth and Death in Infancy | CXR | chest X-ray |
| CEU | Clinical Effectiveness Unit | CYP | cytochrome p450 |
| CF | cystic fibrosis | D&C | dilatation and curettage |
| cffDNA | cell free fetal DNA | D&E | dilatation and evacuation |
| CFU | colony-forming units | DARE | Database of Reviews of Effectiveness |
| CGH | comparative genomic hybridisation | DAT | direct antiglobulin test |
| CGIN | cervical glandular intraepithelial neoplasia | DC | dichorionic |
| CHC | combined hormonal contraception | DC/DA | dichorionic diamniotic |
| CHIVA | Children’s HIV Association | DES | diethylstilbestrol |
| CHM | complete hydatidiform mole | DEXA | bone mineral density scan |
| CI | confidence interval | DF | degrees of freedom |
| CIGN | cervical intraepithelial glandular neoplasia | DFID | Department for International Development |
| CIN | cervical intraepithelial neoplasia | DH | Department of Health |
| CIS | carcinoma <i>in situ</i> | DHEA | dehydroepiandrosterone |
| CKD | chronic kidney disease | DHT | dihydrotestosterone |
| CL | corpus luteum | DI | donor insemination |
| CMA | Canadian Medical Association | DIC | disseminated intravascular coagulopathy |
| CMACE | Centre for Maternal and Child Enquiries | DKA | diabetic ketoacidosis |
| CMV | cytomegalovirus | DLE | diathermy loop excision |
| CNS | central nervous system | DM | diabetes mellitus |
| CNV | copy number variant | DMPA | depot medroxyprogesterone acetate |
| COC(P) | combined oral contraceptive (pill) | DMSO | dimethyl sulphoxide |
| CODAC | cause of death and associated conditions | DOB | date of birth |
| COH | controlled ovarian hyperstimulation | DS | donated sperm |
| COMET | Comparative Obstetric Mobile Epidural Trial | DSD | disorders of sex development |
| COS | controlled ovarian stimulation | dsDNA | double-stranded DNA |
| COX-2 | cyclooxygenase-2 | DV | ductus venosus |
| CP | cerebral palsy | DVP | deepest vertical pool/pocket |
| CPD | cephalo–pelvic disproportion | DVT | deep venous thrombosis |
| CPM | confined placental mosaicism | DySIS | dynamic spectral imaging system |
| CPR | cardiopulmonary resuscitation | DXA | dual-energy X-ray absorptiometry |
| CQC | Care Quality Commission | E2(V) | oestradiol (valerate) |
| CRH | corticotrophin-releasing hormone | E3 | oestriol |
| CRL | crown–rump length | E3G | oestrone-3-glucuronide |
| CRP | C-reactive protein | EAS | external anal sphincter |
| CS | caesarean section | EBM | evidence-based medicine |
| CSA | child sexual abuse | EC | emergency contraception; endometrial carcinoma |
| | | ECG | electrocardiogram |
| | | ECL | echogenic cystic lesion |

| | | | |
|--------|---|---------|--|
| ECOG | Eastern Cooperative Oncology Group | FIGO | International Federation of Gynaecology and Obstetrics |
| ECV | external cephalic version | | |
| EDF | end-diastolic flow | FISH | fluorescence in-situ hybridisation |
| EDTA | ethylenediaminetetraacetic acid | FL | femur length |
| EE | ethinylestradiol | FM | fetal movement |
| EEG | electroencephalogram | FMAIT | fetal maternal alloimmune thrombocytopenia |
| EFM | electronic fetal monitoring | | |
| EFW | estimated fetal weight | FME | forensic medical examiner, previously known as a police surgeon |
| EGF | epidermal growth factor | | |
| eGFR | estimated glomerular filtration rate | FOCSS | familial ovarian cancer screening study |
| EIA | enzyme immunoassay | FRHM | familial recurrent hydatidiform mole |
| EMA | etoposide, methotrexate, actinomycin D | FSH | follicle stimulating hormone |
| | | FSRH | Faculty of Sexual and Reproductive Healthcare |
| EMG | electromyography | | |
| ENA | extractable nuclear antigen | FTA-Abs | fluorescent treponemal antibody absorption (test) |
| ENG | etonogestrel | | |
| EPA | early pregnancy assessment | FTP | failure to progress |
| ER | extended-release; oestrogen receptor | FVL | factor V Leiden |
| ERCP | endoscopic retrograde cholangiopancreatography | GA | general anaesthetic; gestational age |
| | | GABA-A | gamma-aminobutyric acid type A |
| ERCS | elective repeat caesarean section | GAG | glycosaminoglycan |
| ERP | enhanced recovery programme | GBS | group B <i>Streptococcus</i> |
| ERPC | evacuation of products of conception | GCIG | Gynaecologic Cancer Intergroup |
| ERT | oestrogen replacement therapy | G-CSF | granulocyte colony-stimulating factor |
| ESA | erythropoiesis-stimulating agent | GDF | growth differentiation factor |
| eSET | elective single embryo transfer | GDG | Guideline Development Group |
| ESG | European Society of Gynaecology | GDM | gestational diabetes mellitus |
| ESHRE | European Society of Human Reproduction and Embryology | GH | growth hormone |
| | | GHRH | growth hormone-releasing hormone |
| ESMO | European Society of Medical Oncology | GI | glycaemic index |
| ESR | erythrocyte sedimentation rate | GIFT | gamete intrafallopian tube transfer |
| ESSIC | European Society for the Study of Bladder Pain Syndrome/Interstitial Cystitis | GMC | General Medical Council |
| | | GnRH | gonadotrophin-releasing hormone |
| ET | embryo transfer | GOG | Gynecologic Oncology Group |
| ETT | endotracheal tube; epithelial trophoblastic tumour | GP | general practitioner |
| | | GR | glucocorticoid receptor |
| FA | fertility awareness | GRADE | grading of recommendations, assessment, development and evaluation |
| FAI | free androgen index | | |
| FAS | fetal alcohol syndrome | GRIT | Growth Restriction Intervention Trial |
| FBC | full blood count | GS | gestational sac |
| FBS | fetal blood sampling | GT | gestational thrombocytopenia |
| FDA | Food and Drug Administration (USA) | GTD | gestational trophoblastic disease |
| FDP | fibrin degradation product | GTN | gestational trophoblastic neoplasia; glyceryl trinitrate |
| FDV | first desire to void | | |
| FET | frozen embryo transfer | GTT | gestational trophoblastic tumour |
| FEV | forced expiratory volume | GUM | genito-urinary medicine |
| FFLM | Faculty of Forensic and Legal Medicine | HAART | highly active antiretroviral therapy |
| | | HAPO | hyperglycaemia and adverse pregnancy outcomes |
| ffn | fetal fibronectin | Hb | haemoglobin |
| FFP | fresh frozen plasma | HbSS | sickle cell anaemia |
| FFPRHC | Faculty of Family Planning and Reproductive Healthcare | HBV | hepatitis B virus; honour-based violence |
| | | HC | head circumference; hybrid capture |
| FGM | female genital mutilation | hCG | human chorionic gonadotrophin |
| FGR | fetal growth restriction | HCM | hypertrophic cardiomyopathy |
| FHR | fetal heart rate | HCV | hepatitis C virus |

| | | | |
|--------|---|------------|--|
| HDFN | haemolytic disease of the fetus and newborn | IDDM | insulin-dependent diabetes mellitus |
| HDL | high-density lipoprotein | IDU | injecting drug user |
| HDN | haemolytic disease of the newborn | IE | infective endocarditis |
| HDU | high dependency unit | Ig | immunoglobulin |
| HELLP | syndrome of haemolysis, increased liver enzymes and low platelets | IGF-1/2 | insulin-like growth factor 1/2 |
| HERS | Heart and Oestrogen Progestogen Study | IGFBP | insulin-like growth factor binding protein |
| HES | Hospital Episode Statistics | IgG | immunoglobulin G |
| HFEA | Human Fertilisation and Embryology Authority | IgM | immunoglobulin M |
| HGSC | high-grade serous carcinoma | IGT | impaired glucose tolerance |
| HGUS | high-grade undifferentiated sarcoma | IH | immune hydrops |
| HIE | hypoxic–ischaemic encephalopathy | IHD | ischaemic heart disease |
| HIV | human immunodeficiency virus | IIQ | Incontinence Impact Questionnaire |
| HLA | human leukocyte antigen | ILCOR | International Liaison Committee on Resuscitation |
| HMB | heavy menstrual bleeding | IM | intramuscular |
| hMG | human menopausal gonadotrophins | IMB | intermenstrual bleeding |
| HNPCC | hereditary non-polyposis colorectal cancer | IMSI | intracytoplasmic morphological sperm injection |
| HP | hidradenoma papilliferum | INI | integrase inhibitor |
| hPL | human placental lactogen | IOL | induction of labour |
| HPLC | high-performance liquid chromatography | IQ | intelligence quotient |
| HPO | hypothalamic–pituitary–ovarian | IQR | interquartile range |
| HPV | human papilloma virus | ISD | intrinsic sphincter deficiency |
| HQIP | Healthcare Quality Improvement Partnership | ISSHP | International Society for the Study of Hypertension in Pregnancy |
| HR | hazard ratio; high risk | ISSVD | International Society for the Study of Vulvovaginal Diseases |
| HRQoL | health-related quality of life | ISVA | independent sexual violence advisor |
| HRT | hormone replacement therapy | ITP | idiopathic/immune thrombocytopenic purpura |
| HS | harmonic scalpel; hidradenitis suppurativa | ITT | intention to treat |
| HSDD | hypoactive sexual desire disorder | IUCD | intrauterine contraceptive device |
| HSG | hysterosalpingography | IUD | intrauterine death; intrauterine device |
| HSIL | high-grade squamous intraepithelial lesions | IUFD | intrauterine fetal death |
| HSV | herpes simplex virus | IUGA | International Urogynaecology Association |
| HSV-1 | herpes simplex type 1 virus | IUGR | intrauterine growth restriction |
| HSV-2 | herpes simplex type 2 virus | IUI | intrauterine insemination |
| HTA | Health Technology Assessment Database; Human Tissue Authority | IUS | intrauterine system |
| HUS | haemolytic uraemic syndrome | IUT | intrauterine transfusion |
| IADPSG | International Association of Diabetes and Pregnancy Study Group | IV | intravenous |
| IBD | inflammatory bowel disease | IVD | instrumental vaginal delivery |
| IBIS | International Breast Cancer Intervention Study | IVF | in-vitro fertilisation |
| IBS | irritable bowel syndrome | IVF-ET | IVF and embryo transfer |
| IC | interstitial cystitis | IVM | in-vitro maturation |
| ICH | intracranial haemorrhage | IVS | intravaginal slingplasty |
| ICIQ | International Consultation on Incontinence Questionnaire | IVU or IVP | intravenous urogram |
| ICP | intracranial pressure | KHQ | King's Health Questionnaire |
| ICS | International Continence Society; intra-operative cell salvage | LAC | lupus anticoagulant |
| ICSI | intracytoplasmic sperm injection | LAM | lactational amenorrhoea method |
| ICU | intensive care unit | LARC | long-acting reversible contraception |
| | | LBC | liquid-based cytology |
| | | LDH | lactate dehydrogenase |
| | | LDL | low-density lipoprotein |
| | | LEEP | loop electrosurgical excision procedure |
| | | LFT | liver function test |

| | | | |
|-------------|---|---------|--|
| LGESS | low-grade endometrial stromal sarcoma | MI | myocardial infarction |
| LGSC | low-grade serous carcinoma | MIG | metformin with insulin in gestational diabetes |
| LH | lutinising hormone | MIN | multicentric intraepithelial neoplasia |
| LHCGR | shared leutinizing hormone/hCG receptor | MIS | Müllerian inhibiting substance |
| LLETZ | large loop excision of the transformation zone | MLPA | multiplex ligation-dependent probe amplification |
| LMP | last menstrual period | MLS | Maternal Lifestyles Study |
| LMS | leiomyosarcoma | MMF | mycophenolate mofetil |
| LMWH | low-molecular-weight heparin | MMP | matrix metalloproteinase |
| LN | lymph node | MMR | maternal mortality rate |
| LNG | levonorgestrel | MMT | methadone maintenance treatment |
| LNG-IUS | levonorgestrel-releasing intrauterine system | MNC | modified natural cycle |
| LoC-IUT/SDI | letter of competence in intrauterine techniques/subdermal implants | MOET | managing obstetric emergencies and trauma |
| LOD | laparoscopic ovarian drilling | MoM | multiple of the normal median |
| LP | lichen planus | MPA | medroxyprogesterone acetate |
| LS | lichen sclerosus | MPD | maximum pool/pocket depth |
| LSIL | low-grade squamous intraepithelial lesion | MRC | Medical Research Council |
| LUNA | laparoscopic uterine nerve ablation | MRCS | maternal request caesarean section |
| LUTS | lower urinary tract symptom | MRg-FUS | magnetic resonance-guided focused ultrasound |
| LV | liquor volume | MRI | magnetic resonance imaging |
| MA | monoamniotic | MRKH | Mayer–Rokitansky–Kuster–Hauser syndrome |
| MAOI | monoamine oxidase inhibitor | MRSA | methicillin-resistant <i>Staphylococcus aureus</i> |
| MAP | mean arterial pressure; morbidly adherent placenta | MS | multiple sclerosis |
| MAR | mixed antibody reaction | MSAFP | maternal serum alpha-fetoprotein |
| MAS | McCune–Albright syndrome; meconium aspiration syndrome | MSH | melanocyte-stimulating hormone |
| MBRRACE-UK | Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK | MSM | men who have sex with men |
| MC | monochorionic; mucinous carcinoma | MSU | midstream urine |
| MCA | Mental Capacity Act; middle cerebral artery | MSV | Mauriceau–Smellie–Veit |
| MCAD | medium-chain acyl-coenzyme A dehydrogenase deficiency | MTCT | mother-to-child transmission |
| MC/DA | monochorionic diamniotic | MTX/FA | methotrexate with folinic acid |
| MCH | mean corpuscular haemoglobin | MUP | motor nerve unit potential |
| MCHC | mean cell haemoglobin concentration | MVA | manual vacuum aspiration |
| MCV | mean cell volume | MVP | maximum vertical pool/pocket |
| MCP-1 | monocyte chemotactic peptide-1 | NAAT | nucleic acid amplification tests |
| MDG | Millennium Development Goal | NANC | non-adrenergic non-cholinergic |
| MDKD | multicystic dysplastic kidney disease | NAS | neonatal abstinence syndrome |
| MDMA | 3,4-methylenedioxymethamphetamine | NCCN | National Comprehensive Cancer Network |
| MDR | multidrug-resistant | NCEPOD | National Confidential Enquiry into Patient Outcome and Death |
| MDRD | modified diet in renal disease | NCSP | National Chlamydia Screening Programme |
| MDT | multidisciplinary team | NET-EN | norethisterone enanthate |
| MEA | microwave endometrial ablation | NFP | natural family planning |
| MeSH | medical subject heading | NGF | nerve growth factor |
| MEWS | modified early warning system | NHS | National Health Service |
| MFPR | multi-fetal pregnancy reduction | NHSCSP | National Health Service Cervical Screening Programme |
| MG | myasthenia gravis | NHSLA | NHS Litigation Authority |
| MHRA | Medicines and Healthcare products Regulatory Agency | NICE | National Institute for Health and Care Excellence |

| | | | |
|--------|--|----------|---|
| NICHD | National Institute of Child Health and Human Development | PEPSE | post-exposure prophylaxis for HIV following sexual exposure |
| NICU | neonatal intensive care unit | PET | positron emission tomography; |
| NIDDM | non-insulin-dependent diabetes mellitus | PFMT | pre-eclampsia |
| NIH | National Institute of Health; non-immune hydrops | PFMR | pelvic floor muscle training |
| NIPT | non-invasive prenatal testing | PG | peak flow rate |
| NMG | neonatal myasthenia gravis | PHM | prostaglandin |
| NNT | number needed to treat | PI | partial hydatidiform mole |
| NNTB | number needed to treat to benefit | PICO | pulsatility index |
| NOMAC | nomegoestrol acetate | PID | population, intervention, comparison, outcome |
| NPEU | National Perinatal Epidemiology Unit | PIH | pelvic inflammatory disease |
| NPSA | National Patient Safety Agency | PI/r | pregnancy-induced hypertension |
| NRTI | nucleoside reverse transcriptase inhibitor | PIVKA | ritonavir-boosted protease inhibitor |
| NSAID | non-steroidal anti-inflammatory drug | PLCO | prothrombin induced by vitamin K absence |
| NSC | National Screening Committee | PLGF | prostate, lung, colon and ovarian cancer |
| NST | non-stress test | PM | placental growth factor |
| NT | nuchal translucency | PMB | postmortem |
| NTD | neural tube defect | PMCS | post-menopausal bleeding |
| NYHA | New York Heart Association | PMDD | perimortem caesarean section |
| OA | occiput anterior | PMR | premenstrual dysphoric disorder |
| OAA | Obstetric Anaesthetists' Association | PMS | perinatal mortality rate |
| OAB | overactive bladder | PND | premenstrual syndrome |
| OC | obstetric cholestasis | POEC | perinatal death notification |
| OCP | oral contraceptive pill | POI | progesterone-only emergency contraception |
| OCR | optical character recognition | POIC | premature ovarian insufficiency; |
| OGTT | oral glucose tolerance test | POP | progestogen-only implant |
| OHSS | ovarian hyperstimulation syndrome | POP-Q | progestogen-only injectable |
| OI | ovulation induction | PORTEC | contraception |
| OMR | optical mark reader | PORTO | progestogen-only pill |
| ONS | Office for National Statistics | PPH | Pelvic Organ Prolapse Quantification |
| OR | odds ratio | PPI | postoperative radiation therapy in endometrial carcinoma |
| OROS | oxybutynin preparation using an osmotic system | PPIUS | endometrial carcinoma |
| OSAT | objective structured assessment of technical skill | PPROM(T) | prospective observational trial to optimise paediatric health in IUGR |
| OWAM | organisation with a memory | PPS | optimise paediatric health in IUGR |
| PAIS | partial androgen insensitivity syndrome | PPT | postpartum haemorrhage |
| PAMG-1 | placental alpha macroglobulin-1 | PR | postpartum haemorrhage |
| PAPP-A | pregnancy-associated plasma protein-A | PROM | proton pump inhibitor |
| PARP | poly ADP ribose polymerase | PROMPT | proton pump inhibitor |
| PBC | primary biliary cirrhosis | PSN | Patient Perception of Intensity of Urgency Scale |
| PCA | patient-controlled analgesia | PSN | preterm premature rupture of membranes (close to term) |
| PCB | postcoital bleeding | PSTT | membranes (close to term) |
| PCEA | patient-controlled epidural analgesia | PT | pentosan polysulphate |
| PCOS | polycystic ovary syndrome | PTNS | postpartum polysulphate |
| PCR | polymerase chain reaction | PTSD | postpartum thyroiditis |
| PDA | patent ductus arteriosus | PTU | progesterone receptors |
| PDS | polydioxanone suture | PUFAs | pre-labour rupture of membranes |
| PE | pulmonary embolism | | Practical Obstetric Multiprofessional Training |
| PECOT | population, exposure, comparison, outcome and time | | placental site nodule |
| PEEP | positive end-expiratory pressure | | placental site neurectomy |
| PEFR | peak expiratory flow rate | | placental site trophoblastic tumour |
| PEP | post-exposure prophylaxis | | prothrombin time |
| | | | posterior tibial nerve stimulation |
| | | | post-traumatic stress disorder |
| | | | propylthiouracil |
| | | | polyunsaturated fatty acids |

| | | | |
|--------|---|-------|---|
| PUL | pregnancy of unknown location | SGA | small for gestational age |
| PUVA | psoralens and ultraviolet A | SGOT | serum glutamic-oxaloacetic transaminase |
| QALY | quality-adjusted life years | SGPT | serum glutamic pyruvic transaminase |
| QF-PCR | quantitative fluorescence polymerase chain reaction | SHBG | sex hormone-binding globulin |
| QoL | quality of life | SIADH | syndrome of inappropriate anti-diuretic hormone |
| RA | rheumatoid arthritis | SIDS | sudden infant death syndrome |
| RAADP | routine antenatal anti-D prophylaxis | SIGN | Scottish Intercollegiate Guidelines Network |
| RCA | root cause analysis | SIMS | single-incision mini sling |
| RCM | Royal College of Midwives | SLE | systemic lupus erythematosus |
| RCOG | Royal College of Obstetricians and Gynaecologists | SMBE | simulation-based medical education |
| RCPCH | Royal College of Paediatrics and Child Health | SMD | standardised mean difference |
| RCR | Royal College of Radiologists | SMR | severe mental retardation |
| RCT | randomised controlled trial | SNRI | serotonin noradrenaline reuptake inhibitors |
| ReCoDe | Relevant Condition at Death | SOA | Sexual Offences Act |
| REDF | reversed end-diastolic flow | SOAP | subjective, objective, assessment, plan |
| REM | rapid eye movement | SPR | screen positive rate |
| RFM | reduced fetal movement | SPRM | selective progesterone modulator |
| rFSH | recombinant FSH | SROM | spontaneous rupture of membranes |
| Rh | Rhesus | SRY | sex-determining region of the Y chromosome |
| RI | resistance index | SSR | surgical sperm retrieval |
| RiCoF | ristocetin-induced cofactor activity | SSRI | selective serotonin reuptake inhibitor |
| RITA | radiofrequency interstitial thermal ablation | STAN | ST analysis |
| RLU/PC | relative light unit/positive controls | STD | sexually transmitted disease |
| RMI | risk of malignancy index | STI | sexually transmitted infection |
| ROBUST | RCOG operative birth simulation training | STIC | serous tubal intraepithelial carcinoma |
| RPOC | retained products of conception | STUMP | smooth muscle tumour of unknown malignant potential |
| RPR | rapid plasma reagin | STV | short-term variability |
| RR | relative risk | SUDEP | sudden unexpected death in epilepsy |
| RRSO | risk-reducing salpingo-oophorectomy | SVD | spontaneous vaginal delivery |
| RTA | road traffic accident | SVT | supraventricular tachycardia |
| RT-PCR | reverse transcriptase-polymerase chain reaction | T3 | triiodothyronine |
| SADS | sudden adult death syndrome | T4 | thyroxine |
| SANDS | Stillbirth and Neonatal Death Society | TA | transabdominal |
| SARC | sexual assault referral centre | TAH | total abdominal hysterectomy |
| SCBU | special care baby unit | TAMBA | Twins and Multiple Births Association |
| SCC | squamous cell carcinoma | TAP | transversus abdominis plane |
| SCCOHT | small-cell cancer of hypercalcaemic type | TAPS | twin anaemia polycythaemia sequence |
| SCCOPT | small-cell cancer of pulmonary type | TB | tuberculosis |
| SCD | sickle cell disease | TBA | thermal balloon ablation |
| SCD | sudden cardiac death | TBG | thyroid-binding globulin |
| SCI | spinal cord injury | TCA | tricyclic antidepressant |
| SCJ | squamo-columnar junction | TDF | testis-determining factor |
| SD | standard deviation | TED | thromboembolic deterrent/disease |
| SDP | single deepest pool/pocket | TENS | transcutaneous electrical nerve stimulation |
| SDV | strong desire to void | TIA | transient ischaemic attack |
| SEM | static and dynamic surface electromyography | TIBC | total iron-binding capacity |
| sENG | endoglin | TLH | total laparoscopic hysterectomy |
| SERM | selective oestrogen receptor modulator | TM-ET | transmyometrial embryo transfer |
| SFH | symphysis-fundal height | TPHA | <i>Treponema pallidum</i> haemagglutination assay |
| sFLT | soluble fms-like tyrosine kinase-1 | | |

| | | | |
|---------|--|---------|--|
| TRAP | twin reversed arterial perfusion | UT | uterus |
| TRH | thyrotrophin-releasing hormone | UTI | urinary tract infection |
| TRUFFLE | Trial of Randomised Umbilical and Fetal Flow in Europe | UV | umbilical vein |
| TSH | thyroid-stimulating hormone | VACTERL | vertebral, anal, cardiac, trachea-oesophageal, renal, limb association |
| TTN | transient tachypnoea of the newborn | VaIN | vaginal intraepithelial neoplasia |
| TTP | thrombotic thrombocytopenic purpura | VAS | vibro-acoustic stimulation |
| TTTS | twin–twin transfusion syndrome | VBAC | vaginal birth after caesarean section |
| TV | <i>Trichomonas vaginalis</i> | VCU | videocystourethrogram |
| TVS | transvaginal ultrasound scanning | VDRL | Venereal Disease Research Laboratory |
| TVT | tension-free vaginal tape | VEGF | vascular endothelial growth factor |
| UA | umbilical artery | VIN | vulval intraepithelial neoplasia |
| UAE | uterine artery embolisation | VLP | virus-like particles |
| UDCA | ursodeoxycholic acid | VP | vasa praevia |
| UDI | urogenital distress inventory | VSD | ventricular septal defect |
| U&E | urea and electrolyte | VT | ventricular tachycardia |
| uE3 | unconjugated oestriol | VTE | venous thromboembolism |
| UFH | unfractionated heparin | VVA | veno-venous anastomoses |
| UGT | uridine 5'-diphosphate glucuronosyltransferase | vWD | von Willebrand's disease |
| UKGTN | UK Genetic Testing Network | vWF | von Willebrand factor |
| UKMEC | UK Medical Eligibility Criteria | VZIG | varicella zoster IgG |
| UKOSS | UK Obstetric Surveillance System | VZV | varicella-zoster virus |
| UPA | ulipristal acetate | WBC | white blood cell |
| UPP | urethral pressure profilometry | WHI | Women's Health Initiative |
| UPSI | unprotected sexual intercourse | WHO | World Health Organization |
| US(S) | ultrasound (scan) | WHOMEC | WHO Medical Eligibility Criteria |
| USI | urodynamic stress incontinence | WY | woman years |
| | | ZIFT | zygote intrafallopian transfer |

How to use this book

The following features are used throughout the book to highlight the key information and to clearly identify the evidence base.

MRCOG standards

An MRCOG standards box at the start of a chapter lists the relevant standards and/or theoretical and practical skills relating to the topic. Where there are no standards specified in the MRCOG curriculum, we have given a summary of best practice.

EBM

Evidence-based medicine boxes are included to provide a rapid summary of the evidence relating to the interventions and treatments discussed in each chapter. Where evidence is limited, this is also stated.

KEY POINTS

Key points boxes summarise the main points in a section or chapter.

Evidence scoring

It is one of the key principles of this book that doctors assess the quality and applicability of available evidence.

The evidence considered by the authors has been graded according to the structure below, in accordance with the system used in Guidelines published by the RCOG.

Classification of evidence levels

- A** systematic review or meta-analysis
- B** one or more well-designed randomised controlled trials
- C** non-randomised controlled trials, cohort study, etc.
- D** retrospective, uncontrolled
- E** 'expert opinion'

This page intentionally left blank

SECTION ONE

Introductory/General

This page intentionally left blank

Chapter 1 Evidence-based medicine and medical informatics

Jane Thomas

MRCOG standards: Epidemiology and statistics

- Demonstrate the skills needed to critically appraise scientific trials and literature
- Understand the production and application of clinical standards, guidelines and care pathways and protocols
- Understand the difference between audit and research
- Understand how to perform, interpret and use clinical audit cycles
- Understand how to plan a research project
- Demonstrate a full understanding of common usage of computing systems, including the principles of data collection, storage, retrieval, analysis and presentation

INTRODUCTION

This chapter outlines some key concepts of clinical epidemiology and statistics that will help you to understand the terms used within this book, in clinical research and in the MRCOG examination.

Traditionally, medical practice was based on pathophysiological mechanisms of disease and the experience of authoritative experts. The term 'evidence-based medicine' (EBM) was first coined by Gordon Guyatt around 1990 to describe the process of bringing critical appraisal of research evidence to the bedside and basing clinical decisions on clinical research evidence, clinical expertise and patients' values.¹ This title was intentionally provocative.² Developing in parallel with EBM there was recognition that randomised controlled trials are the best way of establishing the effectiveness of treatments, and recognition, that whilst a single study is useful, pooling the findings from all studies provides the best evidence.³ *Effective Care in Pregnancy and Childbirth*⁴ was the first attempt in medicine to look thoroughly for research evidence and

systematically summarise the effect of treatments in a clinical area. This led on to the setting up in 1993 of the Cochrane Collaboration, an international network to prepare, maintain and disseminate systematic reviews.

EBM has evolved, and there is now greater emphasis on evidence in the context of patients' values and preferences. Critical appraisal of a body of evidence takes time, and it is inefficient use of resources to search the literature for every treatment of every patient. Increasingly, therefore, processed research, such as systematic reviews, summary digests of reviews or evidence-based clinical guidelines, can offer the highest level evidence on which to base decisions.² Nevertheless, it remains important that clinicians can appreciate the principles of EBM so that they can distinguish what is trustworthy reliable evidence from what is not.² *Testing Treatments*³ and the website 'Bad Science' provide an accessible introduction to the use and abuse of evidence.⁵

The practice of EBM comprises five steps:⁶ these steps are also used by guideline developers to develop evidence-based clinical guidelines:

- 1 defining a clinical question,
- 2 finding the best evidence,
- 3 appraising the evidence for its validity (closeness to the truth), impact (size of effect) and applicability (usefulness in clinical practice),
- 4 integrating the findings of the critical appraisal with clinical expertise and patient values,
- 5 reviewing (auditing) clinical practice and the efficiency of the above steps.

STEP 1. SETTING THE CLINICAL QUESTION

Generating an answerable clinical question that is precise and specific is the basis of EBM. The development of a search strategy will flow from this. Focused clinical questions include four components, abbreviated as 'PICO':^{6,7}

- **P** – the population: a description of the patients, such as their age, parity, clinical problem and the healthcare setting;

- **I** – the intervention(s) (or exposure): these are the main actions, such as treatment, diagnostic test or risk factor;
- **C** – the comparison group: for example, placebo or an alternative treatment;
- **O** – the outcome: for example, the change in health expected as a result of the intervention.

The type of study that will be sought is determined by the type of clinical question. For example, for a question about treatment, the highest level of evidence is based on randomised controlled trials (RCTs); for diagnostic test accuracy, studies that compare the 'new' test to a 'gold standard' test are needed; for questions about prognosis, studies that follow up groups of patients for a specified period of time (cohort studies) are needed. For a question about risk factors, cohort or 'case-control' studies may be more appropriate. For cohort studies, the intervention may be an exposure (rather than a treatment intervention) and additional factors (length of follow-up or time) may be included. This is sometimes a population, exposure, comparison, outcome and time (PECOT) question.⁷

An example of a vague clinical question is: 'Should we use antibiotic prophylaxis at caesarean section?' This question could be focused in a number of ways.

- *Population*: are you interested in all caesarean sections, or a specific subgroup such as emergency or repeat caesarean section? The country in which you are practising, and the resources available, may also be important to specify.
- *Intervention*: antibiotic prophylaxis. Do you want to specify the antibiotic? Are you interested in the dose/duration of use?
- *Comparison*: is this compared with no antibiotics or with another intervention or another antibiotic – or to a different dose or treatment schedule?
- *Outcome*: what will be different as a result of giving the antibiotics? Will they reduce postoperative wound infection, or other outcomes such as endometritis or urinary tract infection (UTI), or other measures of febrile or infective morbidity such as length of hospital stay? What are the possible adverse effects or risks, for example allergy? What are the longer-term problems for mother or baby?

An example of a focused question is: 'For women having emergency caesarean section, does co-amoxiclav reduce the risk of postoperative endometritis compared with amoxicillin?' This is a question about treatment, so we would look for systematic reviews of randomised control trials.

STEP 2. FINDING THE BEST EVIDENCE

Where to search

There are numerous different library databases; different databases index different journals and they may be general or topic

specific. MEDLINE is produced by the US National Library of Medicine and is widely available free of charge through PubMed. EMBASE has a greater European emphasis in terms of the journals it indexes and has a higher level of pharmacologic content. Nursing and midwifery research may not be indexed by MEDLINE or EMBASE: to find such research, databases such as MIDIRS, BNI and CINAHL should be searched. Psychological literature is indexed on Psychinfo or Psychlit. The best resource for high-quality systematic reviews is the Cochrane Library:

- Cochrane Database of Systematic Reviews (CDSR)
- Database of Reviews of Effectiveness (DARE)
- Health Technology Assessment Database (HTA) (this includes UK and international HTA assessments).

DARE and HTA are also available on www.tripdatabase.com and www.crd.york.ac.uk. The latter also includes a new database, PROSPERO, an international prospective database of systematic reviews in health and social care. Systematic reviews are often also published in peer-reviewed journals and are indexed on library databases. The Cochrane Library has the Cochrane Central Register of Controlled Trials (CENTRAL). In addition, it can be useful to include a citation search of ISI Web of Science or SCOPUS, which will locate research papers that have referenced the papers you intend to include in your research.

There are two online databases specifically for guidelines:

- 1 AHRQ National Guidelines Clearing House, www.guideline.gov (2500 guidelines, free to search and with links to most guidelines)
- 2 The Guidelines International Network library, <http://www.g-i-n.net/library/international-guidelines-library>, with 6500 guidelines, is free to search but you need membership to access guidelines.

Summaries of guidelines are now often also published in journals. If included in the guidelines clearing house they can be found through PubMed, a search of Turning Research Into Practice (TRIP) www.tripdatabase.com or alternatively an internet search for the websites of guideline producers such as NICE SIGN or specialist societies.

- Scottish Intercollegiate Guidelines Network (SIGN) (<http://www.sign.ac.uk/index.html>)
- National Institute for Health and Care Excellence (NICE) (<http://guidance.nice.org.uk/CG/Published>)
- Royal College of Obstetricians and Gynaecologists (RCOG): <http://www.rcog.org.uk>
- Canadian Medical Association (CMA) (<http://www.cma.ca/clinicalresources/practiceguidelines>)

Developing a search strategy

Within general library databases, methodological indexing of study design has greatly improved. Specific strings of search terms that identify study designs, for example systematic

reviews or RCTs, are available: these are designed to have high sensitivity. A good example of these is available in the Cochrane Handbook⁸ – search filters. There are methodological filters, which aim to include all relevant papers, but this may result in relatively low precision. Making your search more precise may be at the expense of sensitivity, i.e. a higher proportion of citations retrieved by your search may be relevant, but it might not include all relevant citations on the topic if these have not been indexed in a way that the filters would pick up.

Developing a search strategy usually involves combining free text and controlled text terms. Using the components of your clinical question (population, intervention, comparison, outcome and study design), make a list of the synonyms, abbreviations and spelling variations (e.g. labor or labour) that might have been used by the authors to describe the concept. If you already know of relevant papers, scan them for more possible search terms. This list can be your ‘free text’ terms.

The next stage is to list useful controlled text terms or subject headings. In MEDLINE, these are known as MeSH (Medical Subject Headings). In most databases they will be found in the thesaurus or index. If you know of a relevant paper, check the subject headings under which it is indexed.

Having developed a focused four-part question (PICO), create a separate search strategy for each component. The next stage is to combine these searches. Combination is achieved by ‘Boolean Logic’ and works in a manner similar to combining numbers in algebra. Boolean Logic uses the terms ‘and’, ‘or’ and ‘not’ to create a set of results that should contain papers relevant to the clinical question. For example, combining cervical *and* cancer will retrieve all the papers that contain both terms. Combining cervical *or* cancer will retrieve all papers in which either one or both terms are found. To find papers relating to postoperative infection, it would be necessary to combine both the lists of controlled and free text terms for both words with *or*. Combining induction *not* labour will retrieve all papers that contain the word induction but do not also include the term labour. Care should be used when combining terms with *not*, as it will exclude any papers that discuss both the term of interest and the one to be excluded. All databases also have useful search commands and symbols, but these vary among databases.

If you are conducting a systematic review, either for publication or as the evidence base for a guideline, it is good practice to keep your search strategies and record:

- how many articles were found by the search,
- the number and source of any other records identified,
- any duplicate reports, which should be removed
- the number of records screened
- the number of full text records assessed,
- those included in a qualitative and quantitative assessment (a meta-analysis),
- exclusions – with the reason.

This information should be combined into a flow chart and published along with your review.⁹

STEP 3. APPRAISING THE EVIDENCE

The best evidence for guiding practice is an accurate, complete summation of current research knowledge such as systematic reviews.³ In order to minimise bias, the methods of a systematic review should be explicit and well structured⁹ and should include clearly defined PICO questions, an extensive search of the literature, appraising the quality of studies located by the search with explicit criteria, and analysing the research findings using appropriate methods. Data from each of the individual studies may be pooled and analysed using a technique known as meta-analysis. Clinical guidelines should be based on systematic reviews, so it is important that you are able to understand the principles of appraising clinical guidelines, systematic reviews and the primary studies on which they are based, so that you are able to judge the validity and applicability of the conclusions to your specific circumstances.

Improved reporting standards of primary and secondary research through statements such as PRISMA,⁹ CONSORT 2010,¹⁰ STARD¹¹ and STROBE¹² ensure the information necessary for critical appraisal is more likely to be available. In addition there are numerous guides to critical appraisal.^{6,13}

Critical appraisal is the process of deciding if the research you have found can help you in answering your clinical question. The first filter is: ‘Does this paper address my clinical question?’ (i.e. is PICO the same or similar to that in your question?) If there are some slight differences, what are these?⁶

The second stage is to look at the study design (the methods section of a paper). The acceptable study design is determined by your clinical question. For questions about treatment interventions, RCTs or systematic reviews of RCTs provide the least biased estimate of effectiveness.^{3,6,8} For diagnostic test accuracy, studies that compare the ‘new’ test to a ‘gold standard’ test are needed. For questions about prognosis, studies that follow up groups of patients for a specified period of time (cohort studies) are needed.

Bias

A systematic review summarises the results from a body of research, usually RCTs but also observational studies. Quality assessment is an essential part of the process of systematic review. If the ‘constituent studies’ are flawed, the conclusions of systematic reviews may also not be valid.^{6,13} Bias is a systematic difference between groups that distorts the comparison so that the ‘true’ effect is either exaggerated or reduced. The quality of a study is the degree to which the study design, conduct and analysis have minimised bias. External validity examines the extent to which the results of a study are applicable to other clinical circumstances, i.e. its generalisability. Internal validity examines the extent to which systematic error (or bias) is minimised within the study. Such biases include:

- **selection bias** – the difference in the patient characteristics (such as prognosis) between comparison groups. In an RCT this is minimised by the method of randomisation

(only non-predictable is acceptable) and by keeping allocation concealed to prevent subversion;

- **performance bias** – differences in the provision of care apart from the treatment under evaluation (achieved through blinding patients, assessors and analysts);
- **detection bias** – differences in the measurement or assessment of outcomes;
- **attrition bias** – the occurrence and handling of patient withdrawals or attrition;
- **reporting bias** – many outcomes may be measured but may not all be reported, reporting is varied dependent on findings, positive findings are more likely to be published and published sooner.

Different study types are prone to different biases; therefore, there are different validity checklists for different studies based on the conduct, design and analysis.^{6,8} Appraising the quality of a study is dependent not only on what was done but on how the study was reported, and it is essential that the research is published so that the findings contribute to what is known.⁵

Understanding RCTs and systematic reviews of RCTs

For the MRCOG, it is important to understand the design of an RCT and of reviews of RCTs; therefore, the rest of this section focuses only on appraising RCTs. The RCT is the ‘gold standard’ method for evaluating the effectiveness of therapeutic interventions as it gives the least biased estimate of effect of treatment interventions.^{3,5}

A confounder is a factor (such as disease severity) that may influence the choice of treatment and the outcome of care. Confounding is one reason for the tendency of non-randomised trials to overestimate treatment effects when compared with RCTs. With a well-conducted RCT, randomisation will create groups that are comparable with respect to any known or unknown potential confounding factors (providing the sample size is sufficiently large). The key questions to ask when appraising (assessing possible bias and quality) an RCT are outlined below, with an explanation of why these are important.⁸ The first four questions relate to study validity, and the fifth to interpreting the results.

1. Was the assignment of treatment randomised?

The process of randomisation requires that those recruiting to a trial or participating in the trial cannot predict which group the subjects will be allocated to. The process of randomisation involves two stages:

- generation of an unpredictable allocation sequence (random number),
- concealment of this sequence from those enrolling participants in the trials.

Failure to secure the concealment of the sequence may allow selective enrolment depending on prognostic factors.

A trial in which it is possible to predict the treatment allocation is more likely to be biased. The ‘gold standard’ for randomisation used in large multicentre trials is ‘central computer’ randomisation. The use of sealed envelopes (especially if they are not sequentially numbered) may be subverted (for example by holding the envelope up to the light); methods that could be predictable are date of birth, alternate days and hospital number.

2. Were the groups similar at the start of the trial?

The aim of randomisation is the creation of groups that are comparable with respect to any known or unknown potential confounding factors (providing the sample size is sufficiently large). Randomisation reduces bias in those selected for treatment and guarantees that treatment assignment is not based on patients’ prognosis. RCTs will have eligibility criteria, but within these trials report the characteristics of the patients according to the treatment received in Table 1 of the results section. The characteristics (such as age, parity) of the two groups should not be different.

3. Were the groups treated equally?

Apart from the intervention being studied, the groups should be treated identically – differences in treatment between groups may occur if treatment allocation is known. This is called performance bias and can be minimised by standardisation of the care protocol and by ‘blinding’. RCTs may blind patients, and those administering treatment, assessing outcomes and analysing the data. If they are aware of allocation, the treatment of both patient groups may differ or patients themselves may deviate from protocols because of awareness of allocation.

Detection (or measurement) bias applies to the measurement or assessment of the outcome. This should be standardised across all patients. Again, knowledge of treatment allocation may influence assessors. For an objective outcome (such as death), this may be less important, but, for outcomes that are subjective, interpretation may differ if the assessor has prior knowledge of allocation. This bias can be minimised by using objective outcomes and by ensuring that those assessing outcomes are unaware of treatment allocation. This approach is used in surgical RCTs: although the surgeon undertaking the treatment has to be aware of the treatment allocation, identical surgical dressings are used for all patients, and the assessment of recovery is done by another person who is not aware of treatment allocation.

4. Are all the patients accounted for at the conclusion?

The process of randomisation gives us comparable groups at the start of a trial, but results are valid only if we can account for all these patients at the end of the trial. Therefore, once randomised, a patient should be included in the analysis of that group even if he or she discontinues therapy, crosses over